Louie Ngar Yee 4

What Happened
Louie Ngar Yee, a director of MAIA Biotechnology, Inc. (MAIA), received a grant of derivative securities on March 31, 2026 representing the right to acquire 33,748 shares. The transaction is reported as an award/acquisition with an acquisition price listed as $0.00 (i.e., an option grant rather than a market purchase); no cash amount or exercise price is disclosed in the filing. The grant vests 100% on the grant date and is exercisable beginning on that date (per the filing footnote). The Form 4 was filed April 2, 2026.

Key Details

• Transaction date: 2026-03-31; filing date: 2026-04-02 (Form 4).
• Reported transaction type: Award/Grant of derivative securities (code A); 33,748 underlying shares; acquisition price reported $0.00.
• Vesting/exercisability: 100% vested on grant date and exercisable as of grant (per footnote).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Filed within the typical Form 4 reporting window (filed Apr 2 for Mar 31 grant).
• Footnote: Options granted under MAIA’s 2021 Equity Incentive Plan; they represent the right to buy shares and are immediately vested/exercisable.

Context
This was a compensation award (an option grant), not an open-market purchase or sale. Such grants are routine for directors and are reported as derivative securities until (and unless) exercised; immediate vesting means the director could exercise the options right away, but the filing does not show any exercise or sale. Awards signal compensation/retention actions rather than direct insider buying or selling of shares.